About Stromal membrane-associated protein 2
Stromal membrane-associated protein 2 (SMAP2) is a protein
from Homo sapiens identified by UniProt accession
Q8WU79, 429 residues long.
MolForge cross-references it against 0 known binders and
105 disease associations.
Target properties
| Protein name | Stromal membrane-associated protein 2 |
| UniProt accession | Q8WU79 |
| Gene | SMAP2 |
| Organism | Homo sapiens |
| Length | 429 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (105)
Diseases linked to this target (Open Targets).
- mean platelet volume · score 0.39
- platelet count · score 0.37
- platelet component distribution width · score 0.30
- diet measurement · score 0.28
- inflammatory bowel disease · score 0.13
- lymphocyte count · score 0.11
- azoospermia · score 0.10
- sitting height measurement · score 0.09
- male infertility with teratozoospermia due to single gene mutation · score 0.09
- partial chromosome Y deletion · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8WU79-F1 | alphafold | PREDICTED | 62.10 | — |
Amino-acid sequence (429 residues)
MTGKSVKDVD RYQAVLANLL LEEDNKFCAD CQSKGPRWAS WNIGVFICIR CAGIHRNLGV HISRVKSVNL DQWTQEQIQC MQEMGNGKAN RLYEAYLPET FRRPQIDPAV EGFIRDKYEK KKYMDRSLDI NAFRKEKDDK WKRGSEPVPE KKLEPVVFEK VKMPQKKEDP QLPRKSSPKS TAPVMDLLGL DAPVACSIAN SKTSNTLEKD LDLLASVPSP SSSGSRKVVG SMPTAGSAGS VPENLNLFPE PGSKSEEIGK KQLSKDSILS LYGSQTPQMP TQAMFMAPAQ MAYPTAYPSF PGVTPPNSIM GSMMPPPVGM VAQPGASGMV APMAMPAGYM GGMQASMMGV PNGMMTTQQA GYMAGMAAMP QTVYGVQPAQ QLQWNLTQMT QQMAGMNFYG ANGMMNYGQS MSGGNGQAAN QTLSPQMWK
Explore Stromal membrane-associated protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets